Primary Biliary Cholangitis Clinical Trials

A listing of 8 Primary Biliary Cholangitis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Primary Biliary Cholangitis

1 - 8 of 8

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 8 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. The states with the highest number of trials for Primary Biliary Cholangitis participants are Texas, Florida, California and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

NCT06060665

Recruiting

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA). The primary objective is to evaluate the effect of seladelpar treatment at Week 52 compared to placebo based on normalization of alkaline phosphatase (ALP) defined by a composite endpoint of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

03/19/2025

Locations: The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona +37 locations

The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona

California Liver Research Institute, Pasadena, California

University of California (UC) Davis Medical Center, Sacramento, California

California Pacific Medical Center, San Francisco, California

University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora, Colorado

South Denver Gastroenterology, Englewood, Colorado

Florida Research Institute, Lakewood Ranch, Florida

University of Miami - Schiff Center for Liver Diseases, Miami, Florida

Gastro Health Research, Miami, Florida

Covenant Metabolic Specialists, LLC, Sarasota, Florida

Covenant Metabolic Specialists, LLC, Tampa, Florida

Digestive Healthcare of Georgia, Atlanta, Georgia

Tulane University Medical Center, New Orleans, Louisiana

Louisiana Research Center, LLC, Shreveport, Louisiana

Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Henry Ford Health System, Novi, Michigan

University of Minnesota, Minneapolis, Minnesota

Kansas City Research Institute, Kansas City, Missouri

New-York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York

New York University (NYU) Langone Medical Center, New York, New York

Weill Cornell Medicine, New York, New York

University of Rochester Medical Center - Strong Memorial Hospital, Rochester, New York

Gastro Health Research, Liberty Township, Ohio

Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University, Philadelphia, Pennsylvania

UPMC Center for Liver Health, Pittsburgh, Pennsylvania

OGI - Gastro One, Cordova, Tennessee

Galen Hepatology, Hixson, Tennessee

American Research Corporation - San Antonio, TX, Austin, Texas

The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas

Baylor College of Medicine - Baylor Clinic, Houston, Texas

Liver Associates of Texas, P.A., Houston, Texas

Bon Secours Liver Institute of Hampton Roads, Richmond, Virginia

Velocity Clinical Research - Seattle, Seattle, Washington

Stanford University, Seattle, Washington

Conditions: Primary Biliary Cholangitis

Learn More ›

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136

Recruiting

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: Southern California Research Center, Coronado, California +83 locations

Southern California Research Center, Coronado, California

Science 37, Inc (Remote-homebased Telemedicine), Culver City, California

Cedars Sinai Medical Center, Los Angeles, California

University of Colorado, Aurora, Colorado

Covenant Metabolic Specialists, Fort Myers, Florida

UF Hepatology Research at CTRB, Gainesville, Florida

UF Health Gastroenterology- Emerson, Jacksonville, Florida

IHS Health, Kissimmee, Florida

Schiff Center for Liver Diseases, Miami, Florida

Advanced Research Institute, Inc, New Port Richey, Florida

Covenant Research and Clinics, LLC, Sarasota, Florida

Tampa General Hospital, Tampa, Florida

Southeast Clinical Research Center, Dalton, Georgia

Northwestern University, Chicago, Illinois

Loyola University Health System - Loyola Outpatient Center, Maywood, Illinois

University of Iowa Hospitals & Clinics, Iowa City, Iowa

Ochsner Clinic Foundation-Baton Rouge, Baton Rouge, Louisiana

LSU Health Science Center Shreveport, Shreveport, Louisiana

Beth Israel Deaconess, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

Jackson Liver and GI Specialists, Jackson, Mississippi

CHI Health Clinic (Alegent Creighton Clinic)- Gastroenterology-Bergan, Omaha, Nebraska

Cleveland Clinic - Main Campus, Cleveland, Ohio

Einstein Healthcare Network - Einstein Medical Center, Philadelphia, Pennsylvania

Methodist Le Bonheur Healthcare, Memphis, Tennessee

Galen Medical Group, P.C, Tennessee, Tennessee

Amel Med LLC, Austin, Texas

Soma Clinical Trials, Denison, Texas

Liver Associates of Texas, Houston, Texas

Velocity Clinical Research, Waco, Texas

University of Utah Health Care, Salt Lake City, Utah

MedStar Health Research Institute, Fairfax, Virginia

Bon Secours Liver Institute of Hampton Roads Mary Immaculate Hospital, Newport News, Virginia

Bon Secours Richmond Community Hospital LLC d/b/a Bon Secours Liver Institute of Richmond, Richmond, Virginia

Liver Institute Northwest, Seattle, Washington

Glenny Corp S.A, Caba, Not set

Universitair Ziekenhuis Antwerpe UZA, Antwerp, Not set

Cliniques Universitaires Saint-Luc, Brussel, Not set

UZ Gent, Gent, Not set

Gordon and Leslie Diamond Health Care Centre, Division of Gastroenterology, Vancouver, British Columbia

University of Alberta, Edmonton, Not set

CHU Grenoble - Hôpital MICHALLON, Grenoble, Not set

Hopital Claude Huriez-Digestive system disease clinic, Lille, Not set

CHU de NICE- Hospital L'Archet 2, Nice, Not set

Hospital Saint Antoine, Paris, Not set

Nouvel Hospital Civil, Strasbourg, Not set

Hospital Paul Brousse- APHP, Villejuif, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Universitätsklinikum Frankfurt am Main, Frankfurt, Not set

Medizinische Hochschule Hannover (MHH), Hanover, Not set

Universitätsklinikum Schleswig-Holstein, Kiel, Not set

University Hospital Munster, Münster, Not set

University Hospital Tübingen Medical clinic, Tubingen, Not set

St. Josefs-Hospital Wiesbaden, Wiesbaden, Not set

Hillel Yaffe Medical Center, Hadera, Not set

Rambam Medical Center, Haifa, Not set

Carmel Medical Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah Medical Center - Ein Karem, Liver Institute Kiryat Hadassah POB 12000, Jerusalem, Not set

Galilee Medical Center, Nahariyya, Not set

Rabin Medical Center, Petach Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

The Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Universita Politecnica delle Marche- Ospedali Riuniti, Ancona, Not set

Fondazione Ca Granda, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Fondazione IRCCS San Gerardo dei Tintori, Monza, Not set

Azienda Ospedale-Università di Padova, Padova, Not set

Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa, Not set

Istituto Clinico Humanitas, Rozzano, Not set

National Hospital Organization Nagasaki Medical Center, Ōmura, Nagasaki

Ehime University Hospital, Ehime, Not set

Toranomon Hospital, Tokyo, Not set

Juntendo University Hospital, Tokyo, Not set

Amstedam University Medical Centers, Amsterdam, Not set

Radboudumc, Nijmegen, Not set

Erasmus medical center, Rotterdam, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Universitari Parc Tauli, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire

Belfast Health & Social Care Trust (BHSCT) Royal Victoria Hospital, Belfast, Not set

King's College Hospital NHS Foundation Trust, London, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Conditions: Primary Biliary Cholangitis, PBC

Learn More ›

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

NCT06383403

Recruiting

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease. Primary biliary cholangitis is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). The main aim of this study is to determine if elafibranor is better than placebo in reducing ALP levels to a normal value. High ALP levels in the blood can indicate liver disease. There will be three periods in this study: A screening period (up to 8 weeks) to assess whether the participant can take part; a treatment period (up to 52 weeks) where eligible participants will be grouped as per their blood ALP levels and randomly assigned to either receive elafibranor or placebo, and a follow-up period (4 weeks) where participants' health will be monitored. Participants will be twice as likely to receive elafibranor than placebo (2:1 ratio). Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a noninvasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (a noninvasive test that passes a probe on skin to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Southern California Research Center, Coronado, California +91 locations

Southern California Research Center, Coronado, California

Kindred Medical Institute for Clinical Trials, Corona, California

Topgraphy Health, Inc., Los Angeles, California

University of California Los Angeles, Los Angeles, California

University of California, Davis, Sacramento, California

Stanford University Medical Center, Stanford, California

Peak Gastroenterology Associates, Colorado Springs, Colorado

Rocky Mountain Gastroenterology, Littleton, Colorado

International Center for Research, Tampa, Florida

Delta Research Partners, LLC, West Monroe, Louisiana

University of Michigan Health System, Ann Arbor, Michigan

Huron Gastroenterology Associates - Center for Digestive Care, Ypsilanti, Michigan

South Denver Gastroenterology,P.C., Englewood, New Jersey

Southwest Gastroenterology Associates, PC (SWGA), Albuquerque, New Mexico

Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York

NYU Langone Health, New York, New York

Charlotte Gastroenterology & Hepatology, PLLC, Charlotte, North Carolina

Coastal Research Institute, Fayetteville, North Carolina

Gastroenterology Center of the Midsouth, Cordova, Tennessee

Methodist Transplant Physicians, Dallas, Texas

Liver Associates of Texas, P.A., Houston, Texas

Gastro health & Nutrition, Katy, Texas

American Research Corporation at The Texas Liver Institute, San Antonio, Texas

American Research Corporation, San Antonio, Texas

University of Virginia Medical Center, Charlottesville, Virginia

Bon Secours Richmond Community Hospital d/b/a Bon Secours Liver Institute of Richmond, Richmond, Virginia

Velocity Liver Institute NW, Seattle, Washington

Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Not set

Krajska Nemocnice Liberec, Liberec, Not set

Artroscan, Ostrava, Not set

Research Site s.r.o., Plzen, Not set

Institute for Clinical and Experimental Medicine - IKEM, Prague, Not set

Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez, Lille, Not set

Cic Inserm 0802 - CHU Poitiers, Poitiers, Not set

Clinique Pasteur, Toulouse, Not set

Hopital Paul-Brousse - APHP, Villejuif, Not set

Charite Universitatsmedizin Berlin, Berlin, Not set

DRK Kliniken Berlin Mitte, Berlin, Not set

Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt, Frankfurt, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Gastroenterologsiche Studiengesellschaft Herne, Hemer, Not set

Universitaet Des Saarlandes, Homberg, Not set

Liver Study Centre Kiel, Kiel, Not set

EUGASTRO GmbH, Leipzig, Not set

Universitaetsklinikum Muenster, Münster, Not set

Azienda Ospedaliera Universitaria Careggi Di Firenze, Firenze, Not set

Ospedale Policlinico San Martino - IRCCS, Genova, Not set

Azienda Ospedaliero Universitaria Modena, Modena, Not set

Azienda Ospedaliero Universitaria Federico II di Napoli, Naples, Not set

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

IRCCS Istituto clinico humanitas - Humanitas Mirasole spa, Rozzano, Not set

Korea University Ansan Hospital, Ansan si, Not set

Keimyung University Dongsan Hospital, Daegu, Not set

Kyungpook National University Hospital (KNUH), Daegu, Not set

The Catholic University of Korea Daejeon St.Mary's Hospital, Daejeon, Not set

Pusan National University Hospital (PNUH), Pusan, Not set

CHA Bundang Medical Center, CHA University, Seongnam-si, Not set

Seoul National University Bundang Hospital (SNUBH), Seongnam-si, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Not set

NZOZ Twoje Zdrowie EL Sp. z o.o., Elbląg, Not set

Krakowskie Centrum Medyczne Sp.z.o.o - FutureMeds, Kraków, Not set

FutureMeds Warszawa Centrum, Warsaw, Not set

CAROL DAVILA EMERGENCY UNIVERSITARY MILITARY HOSPITAL, Centrul Pentru Studiul Metabolismului, Research Metabolism Center, Bucuresti, Not set

Spital Clinic Dr I Cantacuzino, Bucuresti, Not set

Cluj County Clinical Emergency Hospital, Cluj-Napoca, Not set

Gastromedica Srl, Iaşi, Not set

Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

Hospital General Universitario Gregorio Maranon (HGUGM), Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Hospital De Montecelo, Pontevedra, Not set

Institut d Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Tauli, Sabadell, Not set

Hospital Universitario Marques De Valdecilla, Santander, Not set

Hospital Universitario Rio Hortega, Valladolid, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Aberdeen Royal Infirmary NHS Grampian Grampian Health Board, Aberdeen, Not set

Bradford Royal Infirmary - Bradford Teaching Hospitals NHS Foundation, Bradford, Not set

Frimley Park Hospital - Frimley Health NHS Foundation Trust, Frimley, Not set

Queen Elizabeth University Hospital - Greater Glasgow Health Board, Glasgow, Not set

Hull Royal Infirmary - Hull University Teaching Hospitals NHS Trust, Hull, Not set

Ambrose King Centre-Royal London Hospital-Barts Health NHS Trust, London, Not set

King's College Hospital, London, Not set

The Royal Free Hospital - Royal Free London NHS Foundation Trust, London, Not set

The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital, Newcastle Upon Tyne, Not set

Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, Not set

John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, Not set

Conditions: Primary Biliary Cholangitis

Learn More ›

Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis

NCT06427395

Recruiting

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Zydus US007, Birmingham, Alabama +40 locations

Zydus US007, Birmingham, Alabama

Zydus US013, Los Angeles, California

Zydus US011, Pasadena, California

Zydus US043, Sacramento, California

Zydus US022, Aurora, Colorado

Zydus US037, New Haven, Connecticut

Zydus US027, Jacksonville, Florida

Zydus US006, Lakewood Ranch, Florida

Zydus US005, Miami, Florida

Zydus US020, Marietta, Georgia

Zydus US001, Indianapolis, Indiana

Zydus US035, Rochester, New York

Zydus US002, Charlotte, North Carolina

Zydus US015, Philadelphia, Pennsylvania

Zydus US004, Houston, Texas

Zydus US042, Houston, Texas

Zydus US031, Murray, Utah

Zydus US016, Charlottesville, Virginia

Zydus US039, Richmond, Virginia

Zydus US033, Seattle, Washington

Zydus AR001, Ciudad Autónoma de Buenos Aires, Buenos Aires

Zydus AR007, Ciudad Autónoma de Buenos Aires, Buenos Aires

Zydus AR006, Ciudad Autónoma de Buenos Aires, Buenos Aires

Zydus AR005, Ciudad Autónoma de Buenos Aires, Buenos Aires

Zydus AR003, Ciudad Autónoma de Buenos Aires, Buenos Aires

Zydus AR004, Pilar, Buenos Aires

Zydus TR014, Adana, Not set

Zydus TR016, Altındag, Not set

Zydus TR004, Ankara, Not set

Zydus TR005, Bursa, Not set

Zydus TR017, Cebeci, Not set

Zydus TR008, Gaziantep, Not set

Zydus TR009, Istanbul, Not set

Zydus TR010, Istanbul, Not set

Zydus TR003, Istanbul, Not set

Zydus TR001, Istanbul, Not set

Zydus TR002, Izmir, Not set

Zydus TR013, Izmir, Not set

Zydus TR011, Kocaeli, Not set

Zydus TR015, Melikgazi, Not set

Zydus TR006, Mersin, Not set

Conditions: Primary Biliary Cholangitis

Learn More ›

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168

Recruiting

This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting. PBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many participants with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. In this stu... Read More

Gender:

ALL

Ages:

All

Trial Updated:

02/27/2025

Locations: Southern California Research Center, Coronado, California +22 locations

Southern California Research Center, Coronado, California

South Denver Gastroenterology,P.C., Englewood, Colorado

Schiff Center for Liver Diseases - University of Miami, Miami, Florida

Northwell Health Inc, Center for Liver Disease and Transplantation, Manhasset, New York

Liver Center of Texas, Dallas, Texas

Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas

Velocity Clinical Research, Katy, Texas

Virginia Commonwealth University Medical Center - West Hospital, Richmond, Virginia

Gastro health & Nutrition, Seattle, Washington

Medizinische Universitaetsklinik Graz, Graz, Not set

Medical University Innsbruck, Innsbruck, Not set

Charite Universitatsmedizin Berlin, Berlin, Not set

DRK Kliniken Berlin Mitte, Berlin, Not set

Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Not set

Studiengesellschaft BSF, Halle, Not set

Gastroenterologsiche Studiengesellschaft Herne, Herne, Not set

Universitaet des Saarlandes, Homburg, Not set

Universitaetsklinikum Leipzig, Leipzig, Not set

Aberdeen Royal Infirmary NHS Grampian Grampian Health Board, Aberdeen, Not set

Bradford Royal Infirmary - Bradford Teaching Hospitals NHS Foundation, Bradford, Not set

Hull Royal Infirmary - Hull University Teaching Hospitals NHS Trust, Hull, Not set

King's College Hospital NHS Foundation Trust, London, Not set

The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital, Newcastle, Not set

Conditions: Primary Biliary Cholangitis

Learn More ›

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617

Recruiting

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California +49 locations

SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

California Liver Research Institute, Pasadena, California

University of California, Davis Medical Center, Sacramento, California

California Pacific Medical Center - Sutter Pacific Medical Foundation, San Francisco, California

Connie Frank Transplant Center at UCSF, San Francisco, California

Covenant Metabolic Specialists, LLC, Fort Myers, Florida

Florida Research Institute, Lakewood Ranch, Florida

Schiff Center for Liver Diseases/University of Miami, Miami, Florida

Covenant Metabolic Specialists, LLC, Sarasota, Florida

Piedmont Atlanta Hospital / Piedmont Transplant Institute, Atlanta, Georgia

University of Chicago Medical Center, Chicago, Illinois

University Of Iowa Hospitals And Clinics, Iowa City, Iowa

University of Louisville, Clinical Trials Unit, Louisville, Kentucky

Ochsner Clinic Foundation, Jefferson, Louisiana

University Health System - East Jefferson General Hospital Campus, New Orleans, Louisiana

Mercy Medical Center, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Henry Ford Medical Center - Columbus, Detroit, Michigan

MedStar Health Research Institute / MedStar Georgetown Transplant Institute at Fairfax, Plymouth, Minnesota

Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York

NYU Langone Health, New York, New York

Mount Sinai, New York, New York

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina

University Hosptials Cleveland Medical Center, Cleveland, Ohio

Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania

OM Research LLC, Lancaster, Pennsylvania

Thomas Jefferson University, Philadelphia, Pennsylvania

UPMC Center for Liver Diseases, Pittsburgh, Pennsylvania

Gastro One, Germantown, Tennessee

The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas

University of Texas Southwestern Medical Center, Professional Office Building One, Dallas, Texas

Pinnacle Clinical Research, PLLC, San Antonio, Texas

Maryview Hospital LLC d/b/a Bon Secours Liver Institute of Hampton Roads, Richmond, Virginia

VCU Health Clinical Research Services Unit (CRSU), Richmond, Virginia

Liver Institute Northwest, Seattle, Washington

Pusan National University Hospital, Busan, Not set

Kyungpook National University Hospital, Daegu, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Adana City Training and Research Hospital, Adana, Not set

Ege University, Bornova, Not set

Ankara Bilkent City Hospital, Cankaya, Not set

Gaziantep University Medical Faculty Sahinbey Research and Practice Hospital, Gaziantep, Not set

Uludag University Medical Faculty, Gorukle, Not set

Katip Celebi University, Karabağlar, Not set

Kocaeli University Medical Faculty Hospital, Kocaeli, Not set

Rize Recep Tayyip Erdogan University Training and Research Hospital, Maltepe, Not set

Mersin Universitesi Tip Fakultesi Hastanesi, Mersin, Not set

Marmara University Pendik Training and Research Hospital, Pendik, Not set

Conditions: Primary Biliary Cholangitis

Learn More ›

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735

Recruiting

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/25/2025

Locations: UA Thomas D. Boyer Liver Institute, Tucson, Arizona +37 locations

UA Thomas D. Boyer Liver Institute, Tucson, Arizona

Southern California Research Center - Coronado, Coronado, California

Cedars-Sinai Medical Center, Los Angeles, California

Velocity Clinical Research, Santa Ana, California

Peak Gastroenterology Associates Colorado Springs, Colorado Springs, Colorado

University of Florida Hepatology Research at CTRB, Gainesville, Florida

Florida Research Institute, Lakewood Ranch, Florida

University of Miami Leonard M. Miller School of Medicine, Miami, Florida

Springfield Clinic, Springfield, Illinois

Mercy Medical Center - Mcauley Plaza, Baltimore, Maryland

CommonSpirit Health Research Institute, Omaha, Nebraska

New York University Hepatology Associates, New York, New York

Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina

University of Cincinnati, Cincinnati, Ohio

Einstein Medical Center, Philadelphia, Pennsylvania

Rapid City Medical Center, Rapid City, South Dakota

Vanderbilt Digestive Disease Center, Nashville, Tennessee

Pioneer Research Solutions, Houston, Texas

UVA Health - University of Virginia Health System, Charlottesville, Virginia

Gastrointestinal and Liver Specialists of Tidewater - Digestive and Liver Disease Specialists, Norfolk, Virginia

Liver Institute Northwest, Seattle, Washington

(G.I,R,I) GI Research Institute, Vancouver, British Columbia

Office of Dr. Gauthier, North Bay, Ontario

Toronto General Hospital, Toronto, Ontario

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec

306, Fukui, Not set

313, Fukuoka, Not set

305, Hamamatsu, Not set

308, Hirakata, Not set

309, Hiroshima, Not set

304, Isehara, Not set

303, Itabashi-ku, Not set

312, Kanazawa, Not set

307, Matsumoto, Not set

311, Omura, Not set

302, Sapporo, Not set

Teine Keijinkai Hospital, Sapporo, Not set

314, Yokohama, Not set

Conditions: Primary Biliary Cholangitis

Learn More ›

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

NCT06525311

Recruiting

A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/24/2025

Locations: Arizona Liver Health, Chandler, Arizona +13 locations